Biologics in pediatric chronic rhinosinusitis with nasal polyps: A systematic review of efficacy and safety.

Xolair (omalizumab) - Roche, Novartis

Nucala (mepolizumab) - GSK

Dupixent (dupilumab) - Sanofi, Regeneron

http://www.ncbi.nlm.nih.gov/pubmed/42747120

Antonella Loperfido; Antonio Moffa; Cosimo Galletti; Davide Stivalini; Eugenio De Corso; Ignazio La Mantia; Roberta Anzivino

Sep 17, 2026